New drugs, new ways to target androgens in prostate cancer therapy

June 20, 2012 in Cancer

Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

"In many ways, therapies for have led the way in the fight against the disease," says E. David Crawford, MD, investigator at the University of Colorado Cancer Center and review co-author. "The first effective oral therapy for any cancer was estrogen which was described in 1941. The first cancer biomarker that allowed diagnosis and staging was prostatic acid phosphatase back in 1938. Then there was little progress for over four decades."

During those 40 years, in which early work in prostate cancer led to Nobel prizes for researchers Charles Huggins and Andrew Schally, other capitalized on this research, notably developing hormone therapies targeting estrogen in . But work in prostate cancer stalled.

"What we realized is that production of androgens like testosterone depends on an intact system in which the brain recognizes hormone levels, signals the pituitary to increase or decrease production, and the pituitary in turn sets the testes in motion. Additionally, by targeting the production of androgens by the testes, we could break that system at many other points," Crawford says.

For example, estrogen is similar enough to testosterone that administering estrogen to patients tricked the brain into thinking testosterone hormone levels were high – with high presumed , the brain sent no production signal to the pituitary. But estrogen therapy led to side effects including breast enlargement.

The next class of drugs, known as luteinizing hormone releasing hormones or LHRHs, intervened in this signaling chain at the level of the pituitary. Just as keeps the brain from signaling for more testosterone, LHRHs keep the pituitary from passing messages to the testes.

"Because the effects of LHRHs are reversible, this allowed us to use hormone-targeting therapies much earlier in the disease," Crawford says. "But LHRHs lead to an initial spike in testosterone, before it decreases." Most patients can withstand this spike, but for some, for example those with bone metastasis in the back, a spike in testosterone could flare the disease and lead to spinal complications.

"It was only about ten years ago that somebody was able to make a usable antagonist," Crawford says. Instead of first spiking and then lowering testosterone, these LHRH antagonists lead to an immediate drop.

And instead of targeting the signaling pathway that leads to the production of androgens including testosterone, androgen antagonists like Enzalutamide (formerly known as MDV3100), currently in phase III clinical trials, target cells' ability to trap testosterone that exists in the body – it doesn't matter how much testosterone is floating around, as long as are unable to grab it. Specifically, Enzalutamide and other androgen antagonists are easier to "catch" than the androgens themselves, and so cells grab Enzalutamide and are then unable to grab .

Also new to the field are drugs that block the production of androgens from all sources which of course includes the testes, but also includes blocking the smaller amounts produced by the adrenals and even by the cancer itself. This class of drugs is called androgen biosynthesis inhibitors, and the first approved is a drug called abiraterone or Zytiga.

"Targeting cells' androgen receptors is a new and exciting development in the field of prostate cancer therapy," Crawford says. "As these new drugs make their way from the lab to clinic, we expect the ability to offer androgen antagonists to patients whose cancers have resisted other treatments."

Provided by University of Colorado Denver search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

New fluorescent tools for cancer diagnosis

In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...

Cancer created May 24, 2013 | popularity not rated yet | comments 0

Modulating the immune system to combat metastatic cancer

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...

Cancer created May 24, 2013 | popularity 5 / 5 (1) | comments 0

Scientists put bowel cancer under the microscope

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

Cancer created May 24, 2013 | popularity 5 / 5 (1) | comments 0

Researcher identifies breast cancer fighting hormone

Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.

Cancer created May 24, 2013 | popularity 5 / 5 (2) | comments 0

Ground breaking cancer research finds immune system link

(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.

Cancer created May 24, 2013 | popularity 5 / 5 (4) | comments 0


First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...

Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

Seniors more likely to crash when driving with pet, study finds

(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...

New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.

Death highest in heart failure patients admitted in January, on Friday, and overnight

Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

Feds fight morning-after pill age ruling in NY

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...